1. DI-010 Factors influencing the appearance of haematological and thyroid adverse effects in patients with hepatitis C virus genotype 1 treated with telaprevir/boceprevir plus peg-interferon and ribavirin. (24th March 2015) Authors: Manzaneque, A; Sotoca, JM; Lens, S; Kostov, B; Codina, C Journal: European journal of hospital pharmacy Issue: Volume 22(2015)Supplement 1 Page Start: A79 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Large genomic deletions of SMAD4, BMPR1A and PTEN in juvenile polyposis. Issue 5 (4th January 2008) Authors: van Hattem, W A; Brosens, L A A; de Leng, W W J; Morsink, F H; Lens, S; Carvalho, R; Giardiello, F M; Offerhaus, G J A Journal: Gut Issue: Volume 57:Issue 5(2008) Page Start: 623 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Late presentation of chronic hepatitis B virus in Spain: a country with access to therapy. (13th November 2019) Authors: Picchio, C; Roel, E; Buti, M; Lens, S; Andrade, R J; Crespo, J; Calleja, J L; Simon, M A; Lazarus, J V Journal: European journal of public health Issue: Volume 29(2019)Supplement 4 Page Start: Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗